HER2-enriched subtype and ERBB2mRNA as predictors of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer: A combined analysis of TBCRC006/023 and PAMELA trials - Prat, A; De Angelis, C; Pascual, T (2018)
(Suppl.): Abstr. 509